Table S3: Total costs of treatment in the MDR-TB cohort, split by intervention & cost category

|  |  |
| --- | --- |
| **Cost category** | MDR-TB cohort (n=100) |
|  | BR alone | Linezolid plus BR | Delamanid plus BR | Bedaquiline plus BR |
| Hospitalisation costs | € 2,817,995 [46.23%] | € 2,739,250 [34.04%] | € 2,636,180 [32.51%] | € 2,403,791 [28.09%] |
| Outpatient care | € 11,919 [<1%] | € 10,715 [<1%] | € 10,755 [<1%] | € 9,833 [<1%] |
| Anti-TB drugs(excluding group 5) | € 3,026,959 [49.65%] | € 2,996,842 [37.25%] | € 2,962,563 [36.54%] | € 2,865,240 [33.48%] |
| Anti-TB drugs group 5 drugs |  | € 2,030,217 [25.23%] | € 2,282,920 [28.16%] | € 3,079,915 [35.99%] |
| Monitoring costs | € 239,279 [<1%] | € 256,867 [03.19%] | € 215,241 [<1%] | € 197,014 [<1%] |
| Treatment ofadverse events costs |  | € 12,091 [0.15%] | € 229 [<1%] | € 1,735 [<1%] |
| Total costs | € 6,096,152 | € 8,045,981 | € 8,107,888 | € 8,557,529 |

Costs reported in € and are 2015 values. Values [in brackets] show the overall percentage the specific cost contributes towards the total costs.
BR: Background regimen; MDR-TB: Multidrug-resistant tuberculosis;